N/A N=55 Randomized Triple-blind Treatment

Blueberry Consumption and Type 2 Diabetes

Type2 Diabetes

Bottom Line

View on ClinicalTrials.gov: NCT02972996 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Apr 2022

Primary outcome: Primary: Blood Pressure — 125.6; 126.0; 74.6; 75.1 mm Hg — p=0.56

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Blueberry (Other); Placebo (Other)
Age: Adult, Older Adult · 45+ yrs
Sex: Male
Sponsor: Albany Research Institute, Inc.
Primary completion: Jun 2018

Outcome Measures

Outcome	Result	p-value
PRIMARY Blood Pressure	125.6; 126.0; 74.6; 75.1	0.56
SECONDARY Hemoglobin A1C	7.1; 7.5	0.03 sig

Summary

Lifestyle strategies that include dietary modification, such as consumption of a plant-based diet, are well recognized in disease prevention and may improve type 2 diabetes. Various components of a plant-based diet may contribute to its beneficial health effects, but there has been keen interest in the possibility that plant polyphenols may have a role. Blueberries are dietary sources of polyphenols, specifically anthocyanins. To date there are few human clinical trials evaluating the beneficial health effects of blueberries in populations with type 2 diabetes. The objective of the study is to determine if freeze-dried blueberries compared to a blueberry placebo will improve cardiometabolic parameters in men with type 2 diabetes.

Eligibility Criteria

Inclusion Criteria

Male
Ages 45 to 75 years at beginning of study
BMI >25 kg/m2
HbA1C > 6.5 and 10% of body weight over the last 6 months; routine participation in heavy exercise
Heavy smokers (>20 cigarettes per day)
Unable or unwilling to give informed consent or communicate with study staff
Other medical, psychiatric, or behavioral factors that in the judgment of the Principal Investigators may interfere with study participation or the ability to follow the intervention protocol
Allergies to blueberries or blueberry products

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02972996). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.